Prevymis

(letermovir)

PREVYMIS 240 MG in 12 ML InjectionPREVYMIS 240 MG Oral Tablet

View 2 more

NO BLACK BOX WARNING

Dosage & administration

* HSCT: 480 mg administered once daily orally or as an intravenous (IV) infusion over 1 hour through 100 days post-transplant.
* Kidney Transplant: 480 mg administered once daily orally or as an IV infusion over 1 hour through 200 days post-transplant.
* PREVYMIS injection must be administered through a sterile 0.2 micron or 0.22 micron polyethersulfone (PES) in-line filter.
* Dosage Adjustment: If PREVYMIS is co-administered with cyclosporine, the dosage of PREVYMIS should be decreased to 240 mg once daily.
* Do not use PREVYMIS injection with IV bags and infusion set materials containing the plasticizer diethylhexyl phthalate (DEHP).

drug label

Prevymis prescribing information

Contact Medical Science Liaison Report Adverse Event

prior authorization

Prevymis prior authorization resources

PDFCoverage Authorization Request

PDFCoverage Authorization Appeals

PDFPrior Authorization Checklist

PDFAppeals Checklist

Learn More

Benefits investigation

Merck Access Program Enrollment Form - Online

Learn More

financial assistance

Prevymis financial assistance options

Co-pay savings program

commercial only

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

under insured

no insurance

goverment insurance

65+

Merck Access Program Enrollment Form - Online

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Prevymis patient education

Getting started on Prevymis

To share resource; ask patient to:

1.Pull out phone

2.Open camera

3.Scan QR code with camera

4.Tap link

Patient toolkit

BRAND PAGESide Effects

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Learn More

Other resources

Learn More

Prevymis FAQs

How is the dosage of Prevymis?Prevymis is available in 4 dosages, including 20 mg/ml Injection 12 ml, 20 mg/ml Injection 24 ml, 240 mg Tab and 480 mg Tab

What does Prevymis treat?Prevymis treats

What is Prevymis made of?Prevymis contains letermovir which is a Cytomegalovirus DNA Terminase Complex Inhibitor

How Is Prevymis Administered?Prevymis is administered as a Injectable or Oral Pill

What Are The Prevymis Mechanism Of Action?Prevymis mechanism of action is Cytochrome P450 2C19 Inducers, Cytochrome P450 2C8 Inhibitors, Cytochrome P450 2C9 Inducers, Cytochrome P450 3A Inhibitors, DNA Terminase Complex Inhibitors, Organic Anion Transporting Polypeptide 1B1 Inhibitors or Organic Anion Transporting Polypeptide 1B3 Inhibitors

FAQ Data Source

Prevymis

Dosage & administration

drug label

Prevymis prescribing information

prior authorization

Prevymis prior authorization resources

Benefits investigation

financial assistance

Prevymis financial assistance options

Co-pay savings program

Foundation programs

patient education

Prevymis patient education

Getting started on Prevymis

Patient toolkit

Other resources

people also ask

Prevymis FAQs